Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27870187 | 1.00 | TRIM24 (0.46) | TRIM24TRIM33ALDH1A1PAX8 | |
| SCHEMBL7752615 | 0.98 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL8749 | 0.90 | — | — | |
| SCHEMBL9297991 | 0.87 | TRIM24 (0.40) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL7142144 | 0.81 | TRIM24 (0.52) | TRIM24TRIM33ALDH1A1 | |
| Formic Acid SCHEMBL28218022 | 0.80 | TRIM24 (0.31) | TRIM24TRIM33 | |
| SCHEMBL16590548 | 0.80 | TRIM24 (0.53) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL1392715 | 0.79 | — | — | |
| SCHEMBL482646 | 0.77 | TRIM24 (0.42) | TRIM24TRIM33ALDH1A1PAX8 | |
| Formic Acid Methyl Ester SCHEMBL28217549 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362023-B1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | GIVAUDAN SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-6951964-B2 | Method for producing macrocyclic ketones | GIVAUDAN SA (CH) | 2005-10-04 | — | — | US | disclosed |
| US-20040082816-A1 | Method for producting macrocyclic ketones | GIVAUDAN SA (CH) | 2004-04-29 | — | — | US | disclosed |
| EP-1362023-A1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | Givaudan SA (CH) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068372-A1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | GIVAUDAN SA (CH) | 2002-09-06 | — | — | WO | disclosed |
| EP-1236707-A1 | Process for the preparation of macrocyclic ketones | Givaudan SA (CH) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082816-A1 | Method for producting macrocyclic ketones | ADH1C, ADH1A, AKR1C3 | TRIM24 3080/4885TRIM33 4354/4885ALDH1A1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.